Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cholesterol Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels

NCT07423598
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

NCT01350141
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
Placebo, PF-04950615 (RN316)
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
29
States / cities
Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

GPur- Luminating Oral Cholesterol Kinetics Pilot Study

NCT03090542
View directory record Official record
Conditions
Cholesterol Absorption
Interventions
clinoptilolite
Dietary Supplement
Lead sponsor
Canadian Collaborative Research Network
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cumming, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 11, 2026, 2:35 AM EDT
Recruiting No phase listed Observational

Lysosomal Acid Lipase (LAL) Deficiency Registry

NCT01633489
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency, LIPA Deficiency, LAL-Deficiency
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
19
States / cities
Phoenix, Arizona • Stanford, California • Miramar, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin D on Lipids

NCT00723385
View directory record Official record
Conditions
Hypercholesterolemia, Vitamin D Deficiency
Interventions
Vitamin D (1000 or 2000 IU/day), Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Sep 11, 2026, 2:35 AM EDT
Completed No phase listed Observational Results available

Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes

NCT01494298
View directory record Official record
Conditions
Type 2 Diabetes, African American, Cholesterol, Lipoprotein, Apolipoprotein
Interventions
Not listed
Lead sponsor
Mercer University
Other
Eligibility
18 Years to 79 Years · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 11, 2026, 2:35 AM EDT
Enrolling by invitation Not applicable Interventional

Virtual Lifestyle Intervention for Weight Management and Cardiovascular Heal

NCT07572721
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Multicomponent Virtual Lifestyle Intervention
Behavioral
Lead sponsor
Truemedicine Inc
Other
Eligibility
30 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol Levels

NCT03175757
View directory record Official record
Conditions
Cholesterol Health
Interventions
Turmeric and Black Cumin Seed, Placebo
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 11, 2026, 2:35 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lipoprotein Interactions and Platelet Function in Healthy Individuals and Those With Lipid Disorders

NCT06747000
View directory record Official record
Conditions
Lipid Disorders
Interventions
Not listed
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
East Providence, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Not applicable Interventional

Reducing Disparities in Primary Prevention of Cardiovascular Disease

NCT01610609
View directory record Official record
Conditions
Cardiovascular Diseases, Cholesterol, LDL
Interventions
Population Health Management Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
35 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Flagstaff, Arizona • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Not applicable Interventional

The Effect of a Scratch Off Prompt on Health Engagement

NCT01401621
View directory record Official record
Conditions
Blood Pressure Check (Hypertension Screening), Cholesterol Test (Lipid Disorder Screening)
Interventions
Scratchoff Prompt: Name of Test, Scratchoff Prompt: Call to Action, Control
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
84,953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 11, 2026, 2:35 AM EDT
Recruiting No phase listed Observational

LCAT (Lecithin Cholesterol Acyl Transferase) Natural History Study

NCT06217588
View directory record Official record
Conditions
LCAT Deficiency
Interventions
Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
40 participants
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT06005597
View directory record Official record
Conditions
Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Interventions
Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo
Combination Product · Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
45
States / cities
Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Phase 4 Interventional

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.

NCT00753779
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
colesevelam HCl tablets, and simvastatin tablets, simvastatin tablets and colesevelam HCl placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
14
States / cities
Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Results available

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

NCT01380730
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Placebo to Evolocumab
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
55
States / cities
Birmingham, Alabama • Tucson, Arizona • Malvern, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Phase 2 Interventional

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

NCT01941836
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Ezetimibe
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
68
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 11, 2026, 2:35 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

NCT00311987
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
3,5-Diiodothyropropionic acid (DITPA) therapy
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Phase 2 Interventional

A Study in People With High Cholesterol

NCT00133380
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PPAR alpha, atorvastatin, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Fayetteville, Arkansas • Stockton, California • Highlands Ranch, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2007 · Synced Sep 11, 2026, 2:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

NCT03393884
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
IMNN-001, Carboplatin, Paclitaxel
Biological · Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Mobile, Alabama • Newport Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Not applicable Interventional

Project WHADE: A Partner-Based Physical Activity Program for Women

NCT06350604
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes, Metabolic Syndrome, Smoking, High Cholesterol, PreDiabetes, Prehypertension
Interventions
Project WHADE: A Partner-Based Physical Activity Program for Women
Behavioral
Lead sponsor
Rowan University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Glassboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Obicetrapib in Combination With Ezetimibe

NCT04770389
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions
Obicetrapib 5mg, Ezetimibe 10mg, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Lincoln, California • Evanston, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Not applicable Interventional

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction

NCT02770313
View directory record Official record
Conditions
Intermittent Fasting
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
21 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 11, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

NCT02207634
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab, Placebo, Background Statin Therapy
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
134
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 11, 2026, 2:35 AM EDT